Revolution Medicines, Inc. - Common Stock (RVMD)

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has a market

Revolution Medicines (NASDAQ:RVMD) said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma. The oral, once-daily RAS(ON) multi-selective inhibitor is approved for adults with metastatic pancreati

The biotech's Rasonque is already available for prescription.

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an annualized basis producing an average annual return of 49.25%. Currently, Revolution Medicines has a market

One of the most successful investors ever really likes this up-and-coming biotech stock.

Could these 2 stocks outperform most GLP-1-focused companies over the medium term?

Small-cap stocks are finally recovering after years of underperforming the major indexes.

Biotech advances RAS-inhibitor pipeline with $3.9B cash and FDA acceptance of daraxonrasib NDA.

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an annualized basis producing an average annual return of 49.88%. Currently, Revolution Medicines has a market

Revolution Medicines (NASDAQ:RVMD) said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer. The company

This billionaire investor is betting big on a revolutionary approach in treating pancreatic cancer.

The company is on the verge of becoming a commercial-stage biotech, with two promising therapies in phase 3 trials.

But is that performance sustainable?

Revolution Medicines could be a revolutionary biotech stock.

These stocks both scored a win in the first half of the year.

REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA’s Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.

These stocks have jumped in the double- and triple-digits.

The company recently wowed investors with clinical trial results.

This pre-commercial biotech is worth more than some drugmakers that generate consistent sales.

This company's potential pancreatic cancer blockbuster could be a watershed moment.

Can the drugmaker justify its valuation?